Detailed Information on Publication Record
2022
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
BLENNOW, Ola, Jon SALMANTON-GARCIA, Piotr NOWAK, Federico ITRI, Van Doesum JAAP et. al.Basic information
Original name
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
Authors
BLENNOW, Ola, Jon SALMANTON-GARCIA (guarantor), Piotr NOWAK, Federico ITRI, Van Doesum JAAP, Alberto LOPEZ-GARCIA, Francesca FARINA, Ozren JAKSIC, Laszlo Imre PINCZES, Yavuz M BILGIN, Iker FALCES-ROMERO, Moraima JIMENEZ, Irati ORMAZABAL-VELEZ, Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), Remy DULERY, Zlate STOJANOSKI, Tobias LAHMER, Noemi FERNANDEZ, Jose-angel HERNANDEZ-RIVAS, Verena PETZER, De Jonge NICK, Andreas GLENTHOJ, De Ramon CRISTINA, Monika M BIERNAT, Nicola FRACCHIOLLA, Avinash AUJAYEB, Van Praet JENS, Martin SCHONLEIN, Gustavo-Adolfo MENDEZ, Chiara CATTANEO, Anna GUIDETTI, Mariarita SCIUME, Emanuele AMMATUNA, Raul CORDOBA, Nicole GARCIA-POUTON, Stefanie GRAEFE, Alba CABIRTA, Dominik WOLF, Anna NORDLANDER, Ramon GARCIA-SANZ, Mario DELIA, Berg Venemyr CAROLINE, Clara BRONES, Di Blasi ROBERTA, De Kort ELIZABETH, Stef MEERS, Sylvain LAMURE, Laura SERRANO, Maria MERELLI, Nicola COPPOLA, Rui BERGANTIM, Caroline BESSON, Milena KOHN, Jessica PETITI, Carolina GARCIA-VIDAL, Michelina DARGENIO, Francois DANION, Marina MACHADO, Rebeca BAILEN-ALMOROX, Martin HOENIGL, Giulia DRAGONETTI, Louis Yi Ann CHAI, Chi Shan KHO, Matteo BONANNI, Raphael LIEVIN, Francesco MARCHESI, Oliver A CORNELY and Livio PAGANO
Edition
American Journal of Hematology, Hoboken, John Wiley & Sons, 2022, 0361-8609
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30205 Hematology
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 12.800
RIV identification code
RIV/00216224:14110/22:00127656
Organization unit
Faculty of Medicine
UT WoS
000816988100001
Keywords in English
omicron SARS-CoV-2 variant; hematological malignancies
Tags
International impact, Reviewed
Změněno: 4/1/2023 12:34, Mgr. Tereza Miškechová
Abstract
V originále
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused high mortality in patients with hematological malignancies (HM). The newly emerged omicron variants of SARS-CoV-2 harbor multiple novel spike protein mutations that raise concerns about vaccine efficiency and antiviral efficacy of the available therapeutic monoclonal antibodies. The first published clinical data in immunocompetent patients have found that infection with omicron variants is associated with reduced vaccine efficiency compared to the delta variants, but decreased hospital admission and mortality. Preliminary, prepublished, data from a large case–control study have shown that the vaccine effect against omicron in immunocompromised patients, including HM patients, is even more reduced, but data regarding clinical outcomes are lacking. The aim of this study was to describe risk factors, antiviral treatment and outcomes of SARSCoV- 2 omicron variant infection in 593 HM patients included in the EPICOVIDEHA registry. (HM). The newly emerged omicron variants of SARS-CoV-2 harbor multiple novel spike protein mutations that raise concerns about vaccine efficiency and antiviral efficacy of the available therapeutic monoclonal antibodies. The first published clinical data in immunocompetent patients have found that infection with omicron variants is associated with reduced vaccine efficiency compared to the delta variants, but decreased hospital admission and mortality. Preliminary, prepublished, data from a large case–control study have shown that the vaccine effect against omicron in immunocompromised patients, including HM patients, is even more reduced, but data regarding clinical outcomes are lacking. The aim of this study was to describe risk factors, antiviral treatment and outcomes of SARSCoV- 2 omicron variant infection in 593 HM patients included in the EPICOVIDEHA registry.